Exelixis Inc (EXEL)
What changed this quarter
- Risk factors — 4 added · 1 removed · new: Pancreatic Neuroendocrine Tumors (pNET) and… +3
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Company overview
Exelixis. A biotech targeting kidney- and liver-cancer markets with the oncology drug cabozantinib.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Exelixis Inc is classified under the Biotech & Health sector. See peers below.
Exelixis Inc key financials
Based on SEC filings · latest quarter (TTM)
Tap a metric name to see its meaning in the glossary.
ETFs holding Exelixis Inc
Per SEC N-PORT · 2026-03-31 · by weight · factual
EXEL on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — valuation and growth vs the Biotech & Health average
Peers · Biotech & Health
EXEL FAQ
What is Exelixis Inc (EXEL)?
Exelixis. A biotech targeting kidney- and liver-cancer markets with the oncology drug cabozantinib.
What sector is Exelixis Inc in?
Exelixis Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Exelixis Inc's key financials?
Based on the latest quarter (TTM) from SEC filings: Revenue growth (YoY) 3.3%, Operating margin 41.1%, Net margin 35.1%, ROE 36.2%, Debt-to-equity 0.00x. Definitions and interpretation are available on Stocklore.
Where can I analyze Exelixis Inc (EXEL) stock?
On Stocklore you can see EXEL's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.